SMARCA4 and cancer: These findings highlight Brg1 as a potential therapeutic target in Wnt-driven intestinal tumourigenesis and illustrate the viability of targeting the somatic stem cell as the ‘cell of origin’ of cancer, which might be particularly valuable in patients with known predisposition to cancer.